Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic
  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings

CAMBRIDGE, Mass., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that clinical data from the first patient treated in VBP101, its Phase 1/2a multicenter, open-label, first-in-human study of trem-cel (formerly VOR33) in patients with acute myeloid leukemia (AML) has been accepted as a late-breaking poster presentation at the 2023 Tandem Meetings, the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place February 15-19 in Orlando, Florida.

Details about the presentation are as follows:

Title: Initial First-in-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias

Abstract Number: LBA14

Poster Display Hours: Thursday, February 16 from 12:00 PM to 8:00 PM ET; Friday, February 17 from 7:30 AM to 7:00 PM ET; and Saturday, February 18 from 7:30 AM to 3:00 PM ET.

Poster Presentation: “Tandem Meetings Poster Reception: Meet the Authors” on Thursday, February 16 from 5:45 PM to 6:45 PM ET.

About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.

Contact:

Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.